Among patients with lung cancer, stigma is associated with negative psychosocial and behavioral outcomes. There is a need to develop psychometrically robust patient-reported outcome measures for stigma that incorporate perspectives of patients diagnosed with lung cancer. As part of our multiphase process of measure development and validation, we report on scale formation and preliminary psychometric evaluation of the Lung Cancer Stigma Inventory (LCSI). Building on previously reported concept elicitation (Phase I) work, Phase II of LCSI development involved item generation and refinement, informed by literature review, provider input, and patient (N ϭ 20) feedback. Phase III focused on initial psychometric scale evaluation in a unique sample of 231 lung cancer patients. Based on provider input and patient cognitive interviews, 49 items were included in a preliminary measure. In an exploratory factor analysis of the 37 retained items, 3 factors emerged: perceived stigma, internalized stigma, and constrained disclosure. Internal consistency of the final, 25-item LCSI scale was high (Cronbach's ␣ ϭ .89), and the 3 subscales demonstrated good internal consistency. The test-retest correlation was high (r ϭ .91), suggesting strong stability of measurement over time. There was good convergent validity between the LCSI and an existing measure of lung cancer stigma, the Cataldo Lung Cancer Stigma Scale (r ϭ .58, p Ͻ .001). In a multiphase process, we have developed a reliable, multidimensional measure of lung cancer stigma, the LCSI. Subsequent work will be conducted to establish further evidence of validity and clinically meaningful change.
needs. Although there are other known environmental and genetic risk factors for lung cancer, smoking is responsible for almost 90% of lung cancer cases (ACS, 2016; Alberg et al., 2013) .
The robust causal connection between smoking and lung cancer underscores the relevance of tobacco control interventions to reduce lung cancer morbidity and mortality, but it may also generate highly salient stigma (i.e., negative appraisal and devaluation) toward lung cancer patients (Bayer & Stuber, 2006) . Lung cancer stigma can be conceptualized as a form of health-related stigma in which a person perceives and potentially internalizes an experience of rejection, blame, or devaluation directly linked to the belief that their behavior (i.e., smoking) has caused their current health condition (i.e., lung cancer; Cataldo, Jahan, & Pongquan, 2012; Van Brakel, 2006) . Emerging evidence suggests pervasive societal stigma toward lung cancer. For example, in an assessment of societal attitudes toward lung versus breast cancer, Sriram and colleagues (2015) reported both explicit and implicit bias toward lung cancer among cancer patients, caregivers, health care providers, and the general public. Other investigations have identified blaming responses and other biased perceptions of clinicians toward their lung cancer patients (Hamann et al., 2013; Morse, Edwardsen, & Gordon, 2008) . In our previous work, 95% of lung cancer patients described experiencing at least one element of perceived stigma (Hamann et al., 2014) .
Social psychological theory points to factors that are most often tied to the internalization of stigma, including (a) guilt and shame (Mak et al., 2007) ; (b) self-blame (Major, Kaiser, & McCoy, 2003) , (c) anticipated stigma (belief that one will be socially stigmatized if they reveal their identity; Quinn & Chaudoir, 2009) , and (d) negative affect (e.g., ashamed, worthless) from perceiving and experiencing stigma within encounters (Major et al., 2003) . Investigations from other health-related domains have focused on adverse effects of stigma, including psychosocial impairment, limited disclosure (Clark, Lindner, Armistead, & Austin, 2003) , social isolation (Turan et al., 2016) , and reduced treatment adherence (Katz et al., 2013; Sweeney & Vanable, 2016) . When examining these factors and consequences, it becomes clear that stigma is commonly perceived as well as internalized within the context of social interactions. In the case of lung cancer, internalized stigma (including self-blame, guilt, and regret) has been associated with negative psychosocial and interpersonal outcomes for lung cancer patients (Chambers et al., 2012; Chapple, Ziebland, & McPherson, 2004; Else-Quest, LoConte, Schiller, & Hyde, 2009; Holland, Kelly, & Weinberger, 2010; LoConte, Else-Quest, Eickhoff, Hyde, & Schiller, 2008; Weiss, Weinberger, Schwerd, & Holland, 2012) . For example, in recent studies, patient-reported lung cancer stigma has been associated with increased depressive symptoms (Cataldo & Brodsky, 2013; Gonzalez & Jacobsen, 2012) , lower quality of life (Cataldo et al., 2012) , delays in medical help-seeking (CarterHarris, Hermann, Schreiber, Weaver, & Rawl, 2014) , and reduced satisfaction with provider communication (Shen, Thomas, & Ostroff, 2015) . In this vein, it has also been argued that lung cancer stigma may be a barrier to treatment adherence, engagement in clinical trials, and other cancer care outcomes (Hamann et al., 2014; Sriram et al., 2015) .
Increased recognition of lung cancer stigma and its potential consequences calls attention to the need for identifying valid and reliable measurement tools to assess lung cancer stigma. To date, most investigators (e.g., Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011; Gonzalez & Jacobsen, 2012) interested in measuring stigma experienced by patients with lung cancer have adapted stigma scales developed for use with HIV (e.g., Berger, Ferrans, & Lashley, 2001 ) and other potentially stigmatized patient populations. While expedient, the potential pitfall of repurposing scales developed for use with other patient populations is that item content most germane to the targeted patient population may be overlooked. In embarking on this multiphase, scale development and validation project, our goal was to develop a psychometrically sound measurement tool for the assessment of stigma experienced by patients with lung cancer. The Lung Cancer Stigma Inventory (LCSI) item pool was guided by themes expressed during a qualitative concept elicitation phase (Phase 1) conducted with patients diagnosed with lung cancer. Inclusion of this qualitative phase of concept elicitation provides investigators with greater confidence that the LCSI captures relevant aspects of the lung cancer stigma experienced by patients with lung cancer. Our approach is consistent with best practices for item and scale development that call for incorporating patient perspectives to identify relevant, populationappropriate constructs and to validate patient-reported outcome (PRO) instruments (Rothrock, Kaiser, & Cella, 2011 ; U.S. Department of Health and Human Services, 2009). Current recommendations for developing PROs emphasize the importance of patient and expert input, including, but not limited to conceptual model development (Phase I); item generation and improvement (Phase II); and psychometric analysis (Phase III).
Accordingly, we have conducted a multiphase process for development and evaluation of a new measure of stigma among lung cancer patients, LCSI. In Phase I, we aimed to establish content validity by developing a conceptual blueprint or framework for item development. To achieve this goal, we conducted qualitative interviews with lung cancer patients and elicited relevant clinical themes (Hamann et al., 2014) . Our qualitative analyses revealed that lung cancer stigma appeared to be a bidimensional construct representing perceived and internalized stigma as well as maladaptive consequences such as social isolation. In the current report, we describe the next phases of measure development for the LCSI, including scale formation (Phase II) and preliminary psychometric evaluation (Phase III). This rigorous, conceptual, and patientengaged measure development and validation process provides a strong foundation to continue our understanding and amelioration of lung cancer stigma.
Method Overview
Building on our conceptual model (Hamann et al., 2014 and Figure 1 shown here) and recommended psychometric methods for the development of PRO measurement tools (e.g., Basch et al., 2015; Rothrock et al., 2011) , Phase II of LCSI development involved item generation and refinement, informed by a review of existing stigma measurement tools, along with provider and patient input. Phase III focused on initial psychometric scale evaluation, with particular emphasis on assessing reliability and convergent validity. The study was approved by appropriate institutional review boards. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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Phase II: Item Generation and Refinement
Item generation involved (a) adapting the wording of items from existing stigma scales for use with lung cancer patients and (b) generating additional items based on the content domains elicited during qualitative interviews with lung cancer patients. We conducted a thorough literature review of existing stigma measurement tools with a focus on lung cancer and other potentially stigmatized health conditions (e.g., HIV, obesity, mental illness, other cancers; see Table 1 for a list). In addition, the coinvestigators (HAH, JSO, SJCL) constructed items that specifically reflected domains (perceived and internalized stigma) and subdomains of the conceptual model (Hamann et al., 2014) . Items were refined through both provider and patient input. Each item was reviewed by one of three multidisciplinary, lung cancer expert teams (each including a thoracic oncology clinician and a psychosocial clinician) to rate (on a scale ranging from 1 to 5) for relevance and clarity (Lynn, 1986; Patrick et al., 2011) .
Highly relevant items (scores averaging 4.0 or higher) were then administered and evaluated using cognitive interview techniques (Willis, 2005; Willis, Royston, & Bercini, 1991) by 20 lung cancer patients treated at outpatient oncology clinics associated with an NCI-designated cancer center in the Southern region of the United States. A primary goal of cognitive interviewing, an evidence-based, qualitative practice of investigating respondents' understanding of
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survey items (Willis, 2005) , is to evaluate whether respondents interpret items in the manner intended by researchers. For our cognitive interviewing process, we used a hybrid approach combining "thinkaloud" in which participants were asked to comment on each item's wording, and suggest, if needed, alternate wording to enhance relevance and clarity of items, followed by "post-test" debriefing for overall acceptability, comprehension, any additional domains, parent study purpose, and referrals to additional resources. Interviewees were also asked to comment on the scale instruction and the Likert-scale response options. Items were evaluated for readability by the FleschKinkaid Grade Level Index readability measure (Kincaid, Fishburne, Rogers, & Chissom, 1975) , with a desired readability of 6th grade or lower level.
Phase III: Psychometric Evaluation
The pool of refined items emerging from Phase II was then field-tested in a multisite sample of 231 lung cancer patients, recruited through outpatient oncology clinics associated with NCIdesignated cancer centers in the Southern and Eastern regions of the United States. Eligible patients were adults (18 years and older) with a lung cancer diagnosis and/or treatment in the last 12 months, who were able to read and comprehend English, and had capacity to comprehend study information (see Figure 2 for information on recruitment).
Participants completed the items, as part of a larger survey, on either a Web based data platform (Research Electronic Data capture; REDCap; Harris et al., 2009) or in paper form. The measures for the current analysis include a demographic/clinical questionnaire, the refined LCSI items, and an existing stigma measure to assess convergent validity, the Cataldo Lung Cancer Stigma Scale (CLCSS; Cataldo et al., 2011) . The CLCSS is a 31-item instrument, adapted from the HIV Stigma Scale (Berger et al., 2001) composed of four subscales: stigma and shame, social isolation, discrimination, and smoking. High internal consistency for the total stigma scale has been demonstrated in multiple lung cancer samples (Cronbach's ␣ ϭ .97 and 0.96; Cataldo et al., 2011; Cataldo & Brodsky, 2013) . Each item is measured on a 4-point Likert-type scale (1 ϭ strongly disagree, 4 ϭ strongly agree), with higher values indicating greater agreement with the item. Surveys were counterbalanced so that half the sample completed the LCSI before the CLCSS, while the other half completed the CLCSS before the LCSI. After initial survey completion, a subset of 88 participants were provided a second administration of only the LCSI items to assess test-retest reliability; 55 participants (63%) returned this retest within 60 days following completion of the initial survey (retest return averaged 20.9 days [SD ϭ 10.6 days] after completion of the initial survey).
Phase III: Statistical Analyses
The psychometric analysis plan followed procedures outlined in Nunnally and Bernstein (1994) . The first round of analyses yielded item means, standard deviations, and item-total correlations; items with standard deviations Ͻ1.0 and/or poor item-total correlations (Ͻ0.25) were removed from further analysis unless determined to be conceptually relevant by the investigators and expert consultants. In the second round of analyses, an exploratory factor analysis (EFA) with oblique (Oblimin) rotation was conducted to determine the underlying structure of the measure. We chose to conduct an EFA instead of a confirmatory factor analysis (CFA); although we had developed a multidimensional model of stigma, we did not have a strong hypothesis regarding the number and types of factors that would emerge. Moreover, this approach is commonly taken in the initial phases/development of a new scale that lacks a previously identified factor structure (Child, 1990) . Items that loaded strongly on a single factor (Ͼ0.40) and that had a unique contribution to this factor (Ͼ0.10 difference between factor values) were maintained. Cronbach's alpha was calculated to assess internal reliability of the total scale and subscales, while convergent validity was assessed by correlating LCSI scores with scores on the CLCSS.
Results

Phase II
The first round of item development identified 240 unique items that were nominated by the investigators for capturing potentially relevant stigma themes. Expert input on item relevance and clarity reduced the item pool to 113. Items were then evaluated using two rounds of cognitive interviews with a total of 20 lung cancer patients (see Table 2 for demographic and clinical characteristics of this sample). After the first round of cognitive interviews (n ϭ 12), the investigators removed 46 items due to the following reported issues: redundancy (16 items [24%]), lack of clarity (13 items [19%] ), difficult/confusing wording (seven items [10%]) or disliked by respondents (10 items [15%]). Removal of these items resulted in 67 remaining items that were then presented to the second round of cognitive interviewee patients (n ϭ 8). On the basis of this additional round of patient feedback, minor modifications to item wording were made, but the items were generally judged as relevant, appropriate, and understandable. Feedback about response options indicated a This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
preference for a 5-point Likert-type scale with a response stem that focused on magnitude of endorsement inclusive of time since the initial diagnosis (as opposed to real time [now] or a fixed time interval). Final investigator evaluation of conceptual clarity reduced the item pool to 49 items. In general, this reduction eliminated items judged to be consequences of stigma (see Figure 1 ) rather than actual manifestations of stigma. The final 49 items had a readability estimate of a 5.7 grade level as determined by the Flesch-Kinkaid Grade Level Index readability measure (Kincaid et al., 1975) . The final instructional set and response stem states, "To what degree has each of the following happened to you since your lung cancer diagnosis?" with 5-point response options ranging from 1 (not at all) to 5 (extremely).
Phase III
Demographic and clinical characteristics of the 231 participating Phase III patients are presented in Table 2 . The average age of participants was 63 years, 64% were female, and almost half were college graduates. Results from an analysis of means, standard deviations, and item-total correlations indicated that 27 items did not have sufficient response variability (standard deviation Ͻ1) and/or strong scale associations (defined by r Ͻ .25). Among these 27 items, 15 were judged as conceptually relevant by investigators and expert consultants and were therefore retained in the analysis. The remaining 12 items were removed from the scale, resulting in 37 items being included for the next analytic step.
Participants with complete data for all 37 items (N ϭ 195; 85%) were included in an open exploratory factor analysis (EFA), used to extract latent factors from the data. Ten factors had eigenvalues Ͼ1.0, with a clear delineation between three strong factors (accounting for 43% of the explained variance) and the other weaker factors (accounting for 24% of explained variance). Based on the presence of these three strong factors, a second EFA was run with a forced three-factor solution for these 37 items (see Table 3 ). An examination of the rotated factors (Oblimin) indicated that 27 items fulfilled factor loading criteria (defined as loading Ͼ.40 and Ͼ.10 difference between factors). Another two items did not meet criteria, but were maintained in Factor 2 because of strong conceptual relevance. Of the total 29 items retained, 11 items were included in Factor 1 (internalized This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
stigma), 12 items in Factor 2 (perceived stigma), and 6 items in Factor 3 (constrained disclosure). Two items on Factor 1 and two items on Factor 2 were removed based on their content redundancy (see italicized items in Table 3 ), resulting in a final total of 25 items (9, 10, and 6 items remained in Factors 1, 2, 3, respectively; final items noted in bold in Table 3 ). The three factors were correlated but somewhat distinct, with a correlation of .48 between Factors 1 and 2, a correlation of .31 between Factors 2 and 3, and a correlation of .30 between Factors 1 and 3 (all ps Ͻ .001).
Reliability. Internal consistency of the final 25-item LCSI scale was high (Cronbach's ␣ ϭ .89) and the subscales also demonstrated good internal consistency (Factor 1 ␣ ϭ .90; Factor 2 ␣ ϭ .74; and Factor 3 ␣ ϭ .82). The test-retest correlation was also high (r ϭ .91 when including prorated data from the 54 participants who completed at least 17 of 25 LCSI items at test and retest intervals; r ϭ .91 when including the 37 participants who completed all LCSI items at both time points), suggesting strong stability of measurement over time. Table 4 details both full scale-and factorlevel (subscale) comparisons between the LCSI and the CLCSS. The Pearson correlation between the full scale LCSI and the full scale CLCSS was r ϭ .58 (p Ͻ .001), demonstrating good convergent validity. Factor-specific correlations indicated that the Internalized Stigma subscale of the LCSI demonstrated modest convergent validity with the total CLCSS scale, r ϭ .39, p Ͻ .01 whereas the Perceived Stigma, r ϭ .49, p Ͻ .01, and the Constrained Disclosure, r ϭ .54, p Ͻ .01 subscales had good convergent validity with the total CLCSS scale. Overall, the correlations indicate that the new LCSI subscales are convergent with the subscales of the CLCSS, while still showing unique assessment of lung cancer stigma concepts.
Convergent validity.
Discussion
Based on current psychometric guidelines for PRO measure development and our conceptual model (Hamann et al., 2014) , we developed a reliable, new measure of lung cancer stigma, the LCSI This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
(scale can be accessed through the National Cancer Institute GridEnabled Measures Database [GEM] https://www.gem-measures .org/Public/MeasureDetail.aspx?midϭ2603&catϭ2). In this article, we report preliminary psychometric analyses demonstrating scale reliability and validity. Three unique, internally consistent, and conceptually relevant factors emerged: perceived stigma, internalized stigma, constrained disclosure. Two factors reflected our Phase I concept elicitation work identifying patient-reported themes of negative appraisal and devaluation from others (perceived stigma), as well as self-blame, guilt, and regret (internalized stigma). Although our initial conceptual model acknowledged social avoidance and disengagement, we were surprised by the strength of the third unique factor (constrained disclosure). The emergence of this third factor of constrained disclosure as a distinct, important element of lung cancer stigma sets the stage for the subsequent development and testing of potential interpersonal intervention pathways (i.e., empathic provider communication skills training, social support) to mitigate the negative effects of lung cancer stigma (e.g., depression, avoidance, inhibited symptom reporting, diminished health related quality of life). Convergent validity was demonstrated by good association between the new LCSI and the existing CLCSS. Despite this association, the two measures are not redundant and include several points of divergence between the various subscales. For example, the LCSI Internalized Stigma factor was only moderately correlated with the total CLCSS. Additionally, the LCSI Constrained Disclosure factor was analytically distinct from a conceptually related factor in the CLCSS (social isolation), suggesting a unique construct reflecting a nuanced interpersonal aspect of stigma. Patient input from the Phase I qualitative interviews revealed aspects of stigma (e.g., social avoidance, disclosure discomfort) that were incorporated into the LCSI item pool. This three dimensional measurement model of the LCSI both enhances the lung stigma measurement literature and provides intra-and interpersonal targets for the subsequent development and testing of psychosocial interventions.
There are some limitations that should be noted and addressed in subsequent research. First, certain content areas, such as perceived stigma attributable to medical providers, did not yield items with strong psychometric properties and therefore were omitted from the final LCSI scale. While conceptually relevant, these items may have been worded in such a way as to capture only overt rather than subtler experiences of perceived stigma encountered during typical interactions with health care providers. We are now conducting observational studies capturing actual patient-provider consultations to gain a better understanding of the nature of perceived stigma attributable to medical care providers. Despite multisite recruitment, our sample had a limited representation of Latina/o, Asian American, and Native American participants. Further investigation with more inclusive samples, including assessments of measurement invariance across groups, will be important to establish the LCSI as an appropriate lung cancer stigma measurement tool for diverse populations. The LCSI is now only available in English and subsequent work is needed to translate this measure into other languages. Our sample size did not allow examination of stability of the results beyond the test-retest correlation analyses. Additional work will be needed to bolster knowledge about response stability. In addition, further work is needed to establish whether this new measurement tool can be used to examine clinically meaningful change in lung cancer stigma for use as a primary outcome measurement tool for planned trials of patient-and providerfocused interventions to mitigate stigma among lung cancer patients, and possible influences on treatment adherence, trial participation, and other outcomes.
Overall, strengths of this study include a rigorous psychometric protocol for scale development and validation characterized by iterative phases involving patient input and data collection. We made a concerted effort to conduct this study with a heterogeneous, clinicbased, multisite sample of patients diagnosed with lung cancer, including never smokers. In addition to following a thorough process of patient-engaged item and scale development, the LCSI was compared to an existing lung cancer stigma survey providing initial evidence for convergent validity. The new 25-item LCSI was found to be stable and internally consistent, with three robust subscales representing relevant constructs identified in patient interviews. Guided both by social psychological theory and other investigations of health-related stigma, subsequent psychometric work will be conducted to establish further evidence of validity. For example, we will examine key associations of stigma with relevant patient-reported (e.g., depressive symptoms), behavioral (e.g., treatment adherence), and other cancer care outcomes. Future effort will also focus on the measure's utility in identifying clinically significant levels of stigma and detecting clinically meaningful change associated with interventions. This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
